We are short diabetes stocks with following average sell prices: LLY 35.30, INCY 4.15, ALKS 9.20, AMLN 11.50 and ALXN 37.6 www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since
Based on our analysis of the presentations at American Diabetes Association’s Annual Meeting in New Orleans, we expect the following stocks to move : LLY, AMLN, ALKS, INCY, HALO,ALXN, MRK AND AZN. Data from all of the above companies is positive. We can easily analyze the data, but predicting the
The market crash has given us a great opportunity to take profits in our short positions. As a sharp bear market rally can take place any moment, we recommend covering AKAM around $13, VMW around $21, AMLN around $12 and RHHBY around $65. Should a sharp rally ensue and you
We have very large gains in AMLN. Consider buying to cover majority, say 90% of the position right here at $20.50 range. Tight stop on the rest. If there is a substantial bounce, consider shorting again. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY
Using our methodology, all of our short positions with the exception of VMW, AMLN and RHBBY should have been covered by now. If not fully scaled out yet, we suggest aggressively covering AFFX, WFR, KEY, GE, ANAD, SNDK, AVID , IBN and MOT. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF
Roche’s acquisition of DNA ( Genentech ) shows change of the company’s long practiced successful strategy by the new CEO. This indicates lack of confidence in the prior strategy. The new strategy is in reality integration of autonomous subsidiaries, although Roche does not characterize this way. We believe there will